A COVID-19 Trial To Fight Pneumonia With Monoclonal Antibodies

Aridis Pharmaceuticals - 1 minute read

  • Announced first patients of Phase 3 clinical trial of AR-301
  • Monoclonal antibody against S. aureus induced pneumonia in patients who are already on mechanical ventilators.
  • Expected to enroll 240 patients at approximately 160 clinical centers in 22 countries.

“While AR-301 does not treat the virus that causes COVID-19 disease, it can potentially mitigate secondary S. aureus bacterial pneumonia, which represents a serious coronavirus complication and a cause of death in such patients”

Vu Truong, Aridis CEO

10 months ago from Aridis Pharmaceuticals's press release via